Rexford Capital Inc. Invests $1.33 Million in Astrazeneca Plc $AZN

Rexford Capital Inc. acquired a new stake in Astrazeneca Plc (NYSE:AZN) during the first quarter, according to its most recent filing with the SEC. The firm acquired 6,728 shares of the company’s stock, valued at approximately $1,327,000. Astrazeneca comprises about 0.9% of Rexford Capital Inc.’s holdings, making the stock its 24th largest position.

Several other institutional investors also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership lifted its stake in shares of Astrazeneca by 552.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock worth $973,603,000 after acquiring an additional 4,697,895 shares during the period. Pictet Asset Management Holding SA acquired a new position in shares of Astrazeneca during the first quarter worth about $675,263,000. Bank of Montreal Can increased its stake in shares of Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after acquiring an additional 2,695,793 shares during the period. Lansforsakringar Fondforvaltning AB publ purchased a new position in Astrazeneca during the first quarter worth about $473,782,000. Finally, ABN AMRO Bank N.V. raised its holdings in Astrazeneca by 32,441.5% during the first quarter. ABN AMRO Bank N.V. now owns 2,445,171 shares of the company’s stock worth $482,158,000 after purchasing an additional 2,437,657 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Trading Down 0.7%

Shares of AZN opened at $189.66 on Wednesday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm’s 50-day moving average is $184.15 and its two-hundred day moving average is $187.47. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The firm has a market capitalization of $294.14 billion, a P/E ratio of 28.48, a PEG ratio of 1.66 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, research analysts predict that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.